Fosamax and Osteonecrosis of the Jaw: Understanding the Biological Plausibility

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Assessment

The legacy domain provided general health and science information, often structured around accessible public data sources such as government health alerts and institutional directories. This foundation supported broad queries on wellness and disease awareness, typically framed for a general audience seeking foundational knowledge. Transitioning from this heritage, the focus now narrows to a specific exposure scenario: the relationship between Fosamax use and the risk of osteonecrosis of the jaw. This pivot moves from general health literacy toward a more targeted occupational or clinical concern, where understanding exposure pathways becomes critical. In this context, the biological plausibility of jawbone complications following bisphosphonate therapy is examined, shifting the emphasis from population-level health information to individualized risk assessment. The bridge concept here is the translation of general health data into actionable insights for professionals who may encounter patients with prolonged Fosamax exposure, thereby reframing the legacy content as a precursor to specialized risk evaluation.

Bridging General Knowledge to Specific Exposure Pathways

Building on the legacy of general health information, this section focuses on the specific exposure pathway of Fosamax (alendronate) and its potential to cause osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The biological plausibility of a causal link between Fosamax and ONJ is supported by mechanistic pathways involving the drug's pharmacology and the unique characteristics of jawbone tissue.

Mechanistic Pathways: How Fosamax Affects Jawbone

Bisphosphonates like alendronate inhibit osteoclast-mediated bone resorption, which is their intended therapeutic effect for increasing bone mass and reducing fracture risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, this suppression of bone turnover can lead to impaired bone remodeling and repair, particularly in the jawbone, which has a high rate of remodeling due to daily mechanical stress from chewing and the presence of teeth. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents, including bisphosphonates, provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research indicates that bisphosphonate treatment affects the jawbone at multiple scales, from tissue mineral density distribution to nanoindentation properties of the bone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). Such alterations may compromise the jawbone's ability to heal after minor trauma, such as tooth extraction, or to resist local infection, thereby creating conditions conducive to ONJ development.

Risk Factors and Clinical Considerations

Known risk factors for ONJ in patients taking bisphosphonates include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning under section 5.4 titled "Osteonecrosis of the Jaw," which states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This warning also notes that ONJ can occur spontaneously and is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The labeling for Fosamax Plus D similarly includes a warning that lists known risk factors and notes that the risk of ONJ may increase with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings provide clinicians and patients with information about the potential for ONJ, though the adequacy of such warnings in preventing harm depends on whether they are effectively communicated and acted upon in clinical practice.

Causation Considerations for Affected Patients

Causation-related considerations for affected patients involve the timeline between exposure and documented harm. The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse effect, its occurrence may be influenced by individual patient factors and the presence of other risk factors. For patients who develop ONJ, the causal link to Fosamax may be supported by the temporal relationship between drug exposure and symptom onset, the biological plausibility of the mechanism, and the recurrence of symptoms upon rechallenge. However, the presence of other risk factors, such as dental procedures or concomitant medications, complicates the attribution of causation in individual cases. In summary, the evidence supports a biologically plausible causal pathway between Fosamax and ONJ, mediated by bisphosphonate-induced suppression of bone turnover and altered jawbone properties. The prescribing information includes warnings about this risk, and the timeline of exposure to harm can vary. For affected patients, causation considerations involve the interplay of drug exposure, individual risk factors, and clinical presentation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the biological plausibility linking Fosamax to osteonecrosis of the jaw?

Fosamax (alendronate) inhibits osteoclast-mediated bone resorption, which suppresses bone turnover. The jawbone has a high remodeling rate due to mechanical stress, making it vulnerable. Multiscale studies show bisphosphonates alter jawbone properties, impairing healing and increasing ONJ risk (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the known risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and pre-existing dental disease. Duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is causation determined for a patient who developed ONJ after Fosamax use?

Causation considers temporal relationship (onset from days to months), biological plausibility, symptom relief upon discontinuation, and recurrence upon rechallenge. However, other risk factors like dental procedures complicate attribution (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.